Bill
Overview and Timeline are the same for every version. Text and Votes below change with the version you select.
Introduced in Senate — Oct 20, 2025
This Act may be cited as the “No Big Blockbuster Bailouts Act”.
(a) In general
Section 1192(e) of the Social Security Act (42 U.S.C. 1320f–1(e)) is amended—
(1)
in paragraph (1), in the matter preceding subparagraph (A), by striking “through (4)” and inserting “and (3)”;
(2)
in paragraph (3)—
(A)
by striking subparagraph (A);
(B)
by redesignating subparagraphs (B) and (C) as subparagraphs (A) and (B), respectively; and
(C)
in subparagraph (A)(iii), as redesignated by subparagraph (B) of this paragraph, by striking “with respect to” and inserting “subject to paragraph (4), with respect to”; and
(3)
by striking paragraph (4) and inserting the following new paragraph:
(4) Treatment of orphan drugs
In the case of a drug that is designated as a drug for one or more rare diseases or conditions and for which the only approved indication (or indications) is for one or more such rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act), paragraph (3)(A) shall be applied by substituting “$400,000,000” for “$200,000,000” in clause (i) of such paragraph.
(b) Application
The amendments made by subsection (a) shall apply with respect to initial price applicability years (as defined in section 1191(b) of the Social Security Act (42 U.S.C. 1320f(b))) beginning on or after January 1, 2028.